Fibrinogen-like protein 2 gene silencing inhibits cardiomyocytes apoptosis, improves heart function of streptozotocin-induced diabetes rats and the molecular mechanism involved

Bioscience Reports

Volumn 35, Issue 3, 2015, Pages 1-7

  Zhenzhong, Zheng ^a   Yafa, Yu ^a,b   Jin, Liang ^a  

^a NANCHANG UNIVERSITY   (China)

^b Department of Cardiology First People's Hospital of Fuzhou City   (China)

Author keywords

Apoptosis; Diabetes; Fibrinogen like protein 2; Heart function; Molecular mechanism; Tumour necrosis factor

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; FIBRINOGEN; FIBRINOGEN-LIKE PROTEIN 2, RAT; TLR4 PROTEIN, RAT; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FIBRINOGEN LIKE PROTEIN 2 GENE; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GLUCOSE BLOOD LEVEL; HEART FUNCTION; HEART MUSCLE CELL; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TUNEL ASSAY; UPREGULATION; ANIMAL; CARDIAC MUSCLE CELL; ELECTROCARDIOGRAPHY; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HEART; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; ELECTROCARDIOGRAPHY; FIBRINOGEN; GENE SILENCING; HEART; MALE; MYOCYTES, CARDIAC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS, SPRAGUE-DAWLEY; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84934890642     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20150078     Document Type: Article

References (21)

1. Zheng, Z.Z., Wang, L., Wu, Y.P., Wang, H.F., Gao, D., Fa, Y., Wei, Y., Wang, M., Zheng, Z. and Peng, J. (2012) Fibrinogen-like protein 2 gene silencing activates angiopoietin/Tie system and induces myocardial microvascular endothelial cells proliferation and cell migration. Biomed. Res. 23, 37-42
2. Zheng, Z.Z., Zhan, J.F., Zhang, Y.L., Wei, Y., Wang, M., Zheng, Z. and Peng, J. (2012) Serum Fgl2 levels elevated in patients with acute coronary syndrome. Health MED J. 6, 2062-2065
3. Ding, J.W., Ning, Q., Liu, M.F., Lai, A., Leibowitz, J., Peltekian, K.M., Cole, E.H., Fung, L.S., Holloway, C., Marsden, P.A. et al. (1997) Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel Fgl2 prothrombinase. J. Virol. 71, 9223-9230 PubMed
4. Levy, G.A., Liu, M., Ding, J., Yuwaraj, S., Leibowitz, J., Marsden, P.A., Ning, Q., Kovalinka, A. and Phillips, M.J. (2000) Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am. J. Pathol. 156, 1217-1225 CrossRef PubMed
5. Marsden, P.A., Ning, Q., Fung, L.S., Luo, X.P., Chen, Y., Mendicino, M., Ghanekar, A., Scott, J.A., Miller, T., Chan, C. et al. (2003) The Fgl2/fibroleukin prothrombinase contributes to immunologically-mediated thrombosis in experimental and human viral hepatitis. J. Clin. Invest. 112, 58-66 CrossRef PubMed
6. Chan, C.W.Y., Chan, M.W.C., Liu, M., Fung, L., Cole, E.H., Leibowitz, J.L., Marsden, P.A., Clark, D.A. and Levy, G.A. (2002) Kinetic analysis of a unique direct prothrombinase, Fgl2, and the identification of a serine residue critical for the prothrombinase activity. J. Immunol. 68, 5170-5177 CrossRef
7. Chan, C.W.Y., Kay, L.S., Khadaroo, R.G., Chan, M.W.C., Lokatoo, S., Young, K.J., Zhang, L., Gorczynski, R.M., Cattral, M., Rotstein, O. et al. (2003) Soluble Fgl2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and preventing maturation of bone marrow-derived dendritic cells. J. Immunol. 170, 4036-4044 CrossRef PubMed
8. Ardestani, A., Paroni, F., Azizi, Z., Kaur, S., Khobragade, V., Yuan, T., Frogne, T., Tao, W., Oberholzer, J., Pattou, F. et al. (2014) MST1 is a key regulator of beta cell apoptosis and dysfunction in diabetes. Nat. Med. 20, 385-397 CrossRef PubMed
9. Leach, L., Gray, C., Staton, S., Babawale, M.O., Gruchy, A., Foster, C., Mayhew, T.M. and James, D.K. (2004) Vascular endothelial cadherin and beta-catenin in human fetoplacental vessels of pregnancies complicated by type 1 diabetes: associations with angiogenesis and perturbed barrier function. Diabetologia 47, 695-709 CrossRef PubMed
10. Myrup, B., Yokoyama, H., Kristiansen, O.P., Østergaard, P.B. and Olivecrona, T. (2004) Release of endothelium-associated proteins into blood by injection of heparin in normal subjects and in patients with type 1 diabetes. Diabet. Med. 21, 1135-1140 CrossRef PubMed
11. Chen, Y., Yang, R., Yao, L., Sun, Z., Wang, R. and Dai, Y (2007) Differential expression of neurotrophins in penises of streptozotocin-induced diabetic rats. J. Androl. 28, 306-312 CrossRef PubMed
12. Wen, H.L., Liang, Z.S., Zhang, R. and Yang, K. (2013) Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy. Cardiovasc. Diabetol. 13, 50 CrossRef
13. Boudina, S. and Abel, E.D. (2007) Diabetic cardiomyopathy revisited. Circulation 115, 3213-3223 CrossRef PubMed
14. Sun, D., Shen, M., Li, J., Li, W., Zhang, Y., Zhao, L., Zhang, Z., Yuan, Y., Wang, H. and Cao, F. (2011) Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc. Diabetol. 10, 4 CrossRef PubMed
15. Tansy, M.G. and Szymkowski, D.E. (2009) The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov. Today 6, 1082-1088 CrossRef
16. Jia, P., Wang, J., Wang, L., Chen, X., Chen, Y., Li, W.Z., Long, R., Chen, J., Shu, Y.W., Liu, K. and Wang, Z.H. (2013) TNF-α upregulates Fgl2 expression in rat myocardial ischemia/reperfusion injury. Microcirculation 20, 524-533 CrossRef PubMed
17. Chae, H.J., Byun, J.O., Chae, S.W., Kim, H.M., Choi, H.I., Pae, H.O., Chung, H.T. and Kim, H.R. (2005) p38 MAPK and NF-kappaB on IL-6 release in human gingival fibroblasts. Immunopharmacol. Immunotoxicol. 27, 631-646 CrossRef PubMed
18. den Dekker, W.K., Cheng, C., Pasterkamp, G. and Duckers, H.J. (2010) Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 209, 314-320 CrossRef PubMed
19. Radin, M.S., Sinha, S., Bhatt, B.A., Dedousis, N. and O'Doherty, R.M. (2008) Inhibition or deletion of the lipopolysaccharide receptor Toll-like receptor-4 confers partial protection against lipid-induced insulin resistance in rodent skeletal muscle. Diabetologia 51, 336-346 CrossRef PubMed
20. Li, H. and Sun, B. (2007) Toll-like receptor 4 in atherosclerosis. J. Cell. Mol. Med. 11, 88-95 CrossRef PubMed
21. Tobias, P. and Curtiss, L.K. (2005) Thematic review series: the immune system and atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis. J. Lipid. Res. 46, 404-411 CrossRef PubMed